home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Bad To The Bone

  December, 13 2007 10:32
your information resource in human molecular genetics

A drug commonly prescribed to diabetes patients may have negative effects on the bone, suggests a paper online in Nature Medicine.

Proper bone strength is maintained by a balance between the activities of the cells that degrade bone -- osteoclasts -- and the cells that build it -- osteoblasts. Rosiglitazone, which is prescribed to people with diabetes to increase their response to insulin, has been associated with increased fracture risk, owing to an inhibitory action on osteoblasts. Ron Evans and colleagues show that, in mice, rosiglitazone also results in the inappropriate maturation of osteoclasts, providing an additional explanation for why thiazolidinediones (the group of drugs including rosiglitazone) can increase fracture risk.

The team found that deletion of the gene encoding the protein PPAR-gamma, the molecular target of rosiglitazone, specifically in the cells that give rise to mature osteoclasts impaired their differentiation, leading to higher bone mass. By contrast, when they used rosiglitazone to activate PPAR-gamma, they saw more osteoclast activity and thinner bones-- osteoporosis.

These results raise the concern that long-term use of rosiglitazone to treat diabetes could lead to osteoporosis.

Author contact:

Ron Evans (The Salk Institute for Biological Studies, La Jolla, CA, USA)
E-mail: evans@salk.edu

Abstract available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.